Cannabinoid receptors and their endogenous agonists

Annual Review of Pharmacology and Toxicology

Volumn 38, Issue , 1998, Pages 179-200

  Felder, Christian C ^a   Glass, Michelle ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Anandamide; Cannabinoids; Fatty acid ethanolamide; Marijuana; Receptors

Indexed keywords

ADENYLATE CYCLASE; ANANDAMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DRONABINOL; RECEPTOR SUBTYPE;

BRAIN TISSUE; CANNABIS ADDICTION; DRUG RECEPTOR BINDING; HUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; TISSUE DISTRIBUTION;

CANNABIS; CANNABIS SATIVA; MAMMALIA;

EID: 0031749186     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.38.1.179     Document Type: Review

References (134)

1. Mechoulam R. 1986, The pharmacology of cannabis sativa. In Cannabinoids as Therapeutic Agents, ed. R Mechoulam, pp. 1-19. Boca Raton, FL: CRC
2. Zias J, Stark H, Sellgman J, Levy R, Werker E, et al. 1993. Early medical use of cannabis. Nature 363:215
3. Grinspoon L, Bakala JB. 1993. Marihuana. The Forbidden Medicine. New Haven, CT: Yale Univ. Press
4. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, et al. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Pain Symptom Manage. 10:89-97
5. Grinspoon L, Bakalar JB, Doblin R. 1995. Marijuana, the AIDS wasting syndrome, and the U.S. government [letter]. N. Engl. J. Med. 333:670-71
6. Howlett AC. 1984. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradiol compounds. Life Sci. 35:1803-10
7. Howlett AC, Fleming RM. 1984. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response of neuroblastoma cell membranes. Mol. Pharmacol. 26:532-38
8. Dewey WL. 1986. Cannabinoid pharmacology. Pharmacol. Rev. 38:151-78
9. Johnson MR, Melvin LS. 1986. The discovery of non-classical cannabinoid analgesic. In Cannabinoids as Therapeutic Agents, ed. CR Mechoulam, pp. 121-45. Boca Raton: CRC
10. Howlett AC, Johnson MR, Melvin LS, Milne GM. 1988. Nonclassical cannabinoid analgesics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 33:297-302
11. Howlett AC, Qualy JM, Khachatrain LL. 1986. Involvement of Gi in the inhibition of adenylate cyclase by cannabinoid drugs. Mol. Pharmacol. 29:307-13
12. Harris LS, Carchman RA, Martin BR. 1978. Evidence for the existence of specific cannabinoid binding sites. Life Sci. 22:1131-37
13. Devane WA, Dysarc FA III, Johnson MR, Mevin LS, Howlett AC. 1988. Determination and characterisation of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:605-13
14. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-64
15. Gerard CM, Mollereau C, Vassart G, Parmentier M. 1991. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279:129-34
16. Abood ME, Ditto KE, Noel MA, Showalter VM, Tao Q. 1997. Isolation and expression of a mouse CB1 cannabinoid receptor gene-comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma-cells. Biochem. Pharmacol. 53:207-14
17. Chakrabarti A, Onaivi ES, Chaudhuri G. 1995. Cloning and sequencing of a cDNA encoding the mouse brain type cannabinoid receptor protein. DNA Sequence 5:385-88
18. Pfister-Genskow M, Weesner GD, Hayes H, Eggen A, Bishop MD. 1997. Physical and genetic localization of the bovine cannabinoid receptor (CNR1) gene to bovine chromosome 9. Mamm. Genome 8:301-2
19. Stubbs L, Chittenden L, Chakrabarti A, Onaivi E. 1996. The gene encoding the central cannabinoid receptor is located in proximal mouse chromosome-4. Mamm. Genome 7:165-66
20. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, et al. 1995. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:3726-31
21. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
22. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessegue B, et al. 1996. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochem. Biophys. Acta 1307:132-36
23. Deleted in proof
24. Buckley NE, Mezey E, Bonner T, Felder C, Glass M, et al. 1997. Development of a CB2 knockout mouse. Symposium on Cannabinoids, 1:57. Burlington, VT: Int. Cannabinoid Res. Soc.
25. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, et al. 1991. Characterization and localization of cannabinoid receptors in the rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:563-83
26. Herkenham M, Lynn AB, de Costa BR, Richfield EK. 1991. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547:267-74
27. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, et al. 1990. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87: 1932-36
28. Glass M, Faull RLM, Dragunow M. 1997. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study on the fetal, neonatal and adult human brain. Neuroscience 77:299-318
29. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. 1994. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63:637-52
30. Pertwee RG, Fernando SR, Nash JE, Coutts AA. 1996. Further evidence for the presence of cannabinoid CB1 receptors in guinea pig small intestine. Br. J. Pharmacol. 118:2199-205
31. Pertwee RG, Fernando SR. 1996. Evidence for the presence of cannabinoid receptors in mouse urinary bladder. Br. J. Pharmacol. 118:2056-58
32. Pertwee RG, Joeadigwe G, Hawksworth GM. 1996. Further evidence for the presence of cannabinoid CB1 receptors in mouse vas-deferens. Eur. J. Pharmacol. 296:169-72
33. Hillard CJ, Gebremedhin D, Lange AR, Campbell WB, Harder DR, et al. 1997. Cannabinoid receptors (CB1) of cerebral arterial muscle cells inhibit L-type calcium current: Does the CB1 receptor play a role in the regulation of cerebral blood flow. Symposium on Cannabinoids, 1:73. Burlington, VT: Int. Cannabinoid Res. Soc.
34. Ishac EJN, Jiang L, Lake KD, Varga K, Abood ME, et al. 1996. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118:2023-28
35. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, et al. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:54-61
36. Rice W, Shannon JM, Burton F, Fieldeldey D. 1997. Expression of a brain-type cannabinoid receptor (CB1) in alveolar type-II cells in the lung - regulation by hydrocortisone. Eur. J. Pharmacol. 327:227-32
37. Schatz ARE, Lee M, Condie RB, Pulaski JT, Kaminski NE. 1997. Cannabinoid receptors CB1 andCB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol. Appl. Pharmacol. 142:278-87
38. Kearn CS, Hillard CJ. 1997. Rat microglial cells express the peripheral-type cannabinoid receptor (CB2) which is negatively coupled to adenylyl cyclase. Symposium on Cannabinoids, 1:61. Burlington, VT: Int. Cannabinoid Res. Soc.
39. Gaoni Y, Mechoulam R. 1964. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1646-47
40. Hollister LE. 1986. Health aspects of cannabis. Pharmacol. Rev. 38:1-20
41. Martin BR, Compton DR, Prescott WR, Barrett RL, Razdan RK. 1995. Pharmacological evaluation of dimethylheptyl analogs of delta 9-THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend. 37:231-40
42. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, et al. 1995. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 38:3094-105
43. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, et al. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:240-44
44. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, et al. 1996. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem. 39:3875-77
45. Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, et al. 1996. New class of potent ligands for the human peripheral cannabinoid receptor. Biol. Med. Chem. Lett. 6:2263-68
46. Barth F, Rinaldi-Carmona M, Millan J, Derocq J, Bouaboula M, et al. 1997. SR144528, a potent and selective antagonist of the CB2 receptor. Symposium on Cannabinoids, 1:11. Burlington, VT: Int. Cannabinoid Res. Soc.
47. Glass M, Felder CC. 1997. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs-linkage to the CB1 receptor. J. Neurosci. 17:5327-33
48. Mackie K, Lai Y, Westenbroek R, Mitchell R. 1995. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in ATT20 cells transfected with rat brain cannabinoid receptors. J. Neurosci. 15:6552-61
49. Mackie K, Hille B. 1992. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA 89:3825-29
50. Caulfield MP, Brown DA. 1992. Cannabinoid receptor agonists inhibit CA current in N9108-15 neuroblastoma cells via a pertussis toxin sensitive mechanism. Br. J. Pharmacol. 106:231-32
51. 2+ channels in a neuronal expression system. Mol. Pharmacol. 49:707-14
52. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, et al. 1995. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:443-50
53. Gifford AN, Ashby CR. 1996. Electrically-evoked acetylcholine-release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN55212-2, and is potentiated by the cannabinoid antagonist, SR141716A. J. Pharmacol. Exp. Ther. 277:1431-36
54. Gessa GL, Mascia MS, Casu MA, Carta G. 1997. Inhibition of hippocampal acetylcholine release by cannabinoids -reversal by SR141716A. Eur. J. Pharmacol. 327:R1-R2
55. Schlicker E, Timm J, Görg T, Göthert M. 1997. Cannabinoid receptor-mediated inhibition of noradrenaline release and cAMP accumulation in the guinea-pig and human brain. Symposium on Cannabinoids, 1:63. Burlington, VT: Int. Cannabinoid Res. Soc.
56. Shen MX, Piser TM, Seybold VS, Thayer SA. 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:4322-34
57. Deadwyler SA, Hampson RE, Mu J, Whyte A, Childers S. 1995. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP dependent process. J. Pharmacol. Exp. Ther. 273:734-43
58. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. 1996. Attenuation of inducible nitric oxide synthase gene-expression by delta(9)-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa-B/Rel activation. Mol. Pharmacol. 50:334-41
59. Coffey RG, Yamamoto Y, Snella E, Pross S. 1996. Tetrahydrocannabinol inhibition of macrophage nitric-oxide production. Biochem. Pharmacol. 52:743-51
60. Bouaboula M, Poinotchazel C, Bourrie B, Canat X, Calandra B, et al. 1996. Activation of mitogen-activated protein-kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312:637-41
61. Bouaboula M, Bourrie B, Rinaldi-Carmona M, Shire D, Le Fur G, et al. 1995. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270:13973-80
62. Glass M, Dragunow M. 1995. Selective induction of Krox 24 in striosomes by a cannabinoid agonist. NeuroReport 6:241-44
63. Reichman M, Nen W, Hokin LE. 1991. Delta-9-tetrahydrocannabinol inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea pig cerebral cortex slices. Mol. Pharmacol. 40:547-55
64. Reichman M, Nen W, Hokin LE. 1988. Delta-9-tetrahydrocannabinol increases arachidonate levels in guinea pig cerebral cortex slices. Mol. Pharmacol. 34:823-28
65. Burnstein S, Hunter SA. 1978. Prostaglandins and cannabis. VI. Release of arachidonic acid from HeLa cells by delta-1-tetrahydrocannabinol and other cannabinoids. Biochem. Pharmacol. 27:1275-80
66. Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. 1992. Cannabinoid agonists stimulate both receptor and non-receptor mediated signal transduction pathways in cells transfected and expressing cannabinoid receptor clones. Mol. Pharmacol. 42:838-45
67. Shivachar AC, Martin BR, Ellis EF. 1996. Anandamide-and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- pyrazole-3-carboximide hydrochloride]. Biochem. Pharmacol. 51:669-76
68. Hunter SA, Burnstein SH. 1997. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci. 60:1563-73
69. Devane WA, Hanus L, Breuer A, Pertwee RG, Sevenson LA, et al. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-49
70. Johnson DE, Heald SL, Dally RD, Janis RA. 1993. Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonist 1,4-dihydropyridine binding. Proslaglandins Leukot. Essent. Fatty Acids 48:429-37
71. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, et al. 1993. Anandamide, an endogenous cannabimetic eiconsanoid, binds to the cloned human cannabinoid receptor and stimulates receptor mediated signal transduction. Proc. Natl. Acad. Sci. USA 90:7656-66
72. Vogel Z, Barg J, Levy R, Saya D, Heldman E, et al. 1993. Anandamide, a brain endogenous compound interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:352-55
73. Childers SR, Sexton T, Roy MB. 1994. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47:711-15
74. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, et al. 1995. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol. 48:352-61
75. Pinto JC, Potie F, Rice KC, Boring D, Johnson MR, et al. 1994. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:516-22
76. Hillard CJ, Edgemond WS, Campbell WB. 1995. Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J. Neurochem. 64:677-83
77. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, et al. 1995. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1172-81
78. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, et al. 1994. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:219-27
79. Fride E, Mechoulam R. 1993. Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur. J. Pharmacol. 231:313-14
80. Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane WA, et al. 1993. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46:967-72
81. Venance L, Piomelli D, Glowinski J, Giaume C. 1995. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376:590-94
82. Lake KD, Martin BR, Kunos G, Varga K. 1997. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29:1204-10
83. Randall MD, Alexander SP, Bennett T, Boyd EA, Fry JR, et al. 1996. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun. 229:114-20
84. Hanus L, Gopher A, Almog S, Mechoulam R. 1993. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:3032-34
85. Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N, et al. 1995. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 287:145-52
86. Thomas BF, Adams IB, Mascarella SW, Martin BR, Razdan RK. 1996. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J. Med. Chem. 39:471-79
87. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. 1997. Structural requirements for binding of anandamide type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:659-67
88. Khanolkar AD, Abadji V, Lin S, Hill WA, Taha G, et al. 1996. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39:4515-19
89. Edgemond WS, Campbell WB, Hillard CJ. 1995. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids 52:83-86
90. Adams IB, Ryan W, Singer M, Razdan RK, Compton DR, et al. 1995. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 56:2041-48
91. Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasson JL, et al. 1995. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375:117-20
92. 2+)-dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun. 218:113-17
93. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, et al. 1996. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide in brain and peripheral tissues of human and rat. FEBS Lett. 393:231-35
94. Wang PC, Buu NT, Kuchel O, Genest J. 1983. Conjugation patterns of endogenous plasma catecholamines in human and rat. A new specific method for analysis of glucuronide-conjugated catecholamines. J. Lab. Clin. Med. 101:141-51
95. Kuehl FA, Jacob TA, Ganley OH, Ormond RE, Meisinger MAP. 1957. The identification of N-(2-hydroyethyl)-palmitamide as a naturally occurring antiinflammatory agent. J. Am. Chem. Soc. 79:5577-78
96. Bachur NR, Udenfriend S. 1965. Microsomal synthesis of fatty acid amides. J. Biol. Chem. 240:1019
97. Schmid HH, Schmid PC, Natarajan V. 1990. N-acylated glycerophospholipids and their derivatives. Prog. Lipid Res. 29:1-43
98. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, et al. 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons [see comments]. Nature 372:686-91
99. Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, et al. 1996. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoyl ethanolamide, an endogenous cannabinoid-receptor ligand, in rat brain microsomes: comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240:53-62
100. Mechoulam R, Ben-Shabat S, Hanus L, Ligumdky M, Kaminski NE, et al. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83-90
101. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, et al. 1997. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322:671-77
102. Di Marzo V, De Petrocellis L, Sugiura T, Waku K. 1996. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227:281-88
103. Sugiura T, Kondo S, Sukagawa A, Tonegawa T, Nakane S, et al. 1996. N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. J. Lipid. Mediat. Cell. Signal 14:51-56
104. Stella N, Schweitez P, Piomelli D. 1997. A second endogenous cannabinoid ligand that modulates long-term potentiation. Nature 388:773-78
105. Devane WA, Axelrod J. 1994. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sci. USA 91:6698-701
106. Kruszka KK, Gross RW 1994. The ATP-and CoA-independent synthesis of arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J. Biol. Chem. 269:14345-48
107. Cadas H, di Tomaso E, Piomelli D. 1997. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17:1226-42
108. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. 1997. Functional role of high-affinity anandamide transport, as revealed by selective-inhibition. Science 277:1094-97
109. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, et al. 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87
110. Deutsch DG, Omeir R, Arreaza G, Salenhani D, Prestwich DG, et al. 1997. Methyl arachidonyl fiuorophoshonate: a potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 53:255-60
111. Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, et al. 1997. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. 231:217-21
112. Muthian SKG, Edgemond WS, Campbell WB, Hillard CJ. 1997. Diazomethyl arachidonoyl ketone irreversibly inhibits amidohydrolase in isolated rat brain membranes, cultured cells and in vivo. Symposium on Cannabinoids, 1:14. Burlington, VT: Int. Cannabinoid Res. Soc.
113. Voth EA, Schwartz RH. 1997. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann. Intern. Med. 126:791-98
114. Hoffman D, Brunneman DK, Gori GB, Wynder EL. 1975. On the carcinogenicity of marijuana smoke. Recent Adv. Phytochem. 9:63-81
115. Wu TC, Tashkin DP, Djahed B, Rose JE. 1983. Pulmonary hazards of smoking marijuana as compared with tobacco. N. Eng. J. Med. 318:347-51
116. Sallan SE, Zinberg NE, Frei E 3d. 1975. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293:795-97
117. Sallan SE, Cronin C, Zelen M, Zinberg NE. 1979. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochloroperazine. N. Engl. J. Med. 302:135-38
118. Chang AE, Shilling DJ, Stillman RC, Goldberg NH, Seipp CA, et al. 1979. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high dose methotrexate. A prospective, randomized evaluation. Ann. Intern. Med. 91:819-24
119. Nelson K, Walsh D, Deeter P, Sheehan F. 1994. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J. Palliative Care 10:14-18
120. Tanda G, Pontieri FE, Di Chiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common m1 opioid receptor mechanism. Science 276:2048-50
121. McGregor IS, Issakidis CN, Prior G. 1996. Aversive effects of the synthetic cannabinoid CP55,940 in rats. Pharmacol. Biochem. Behav. 53:657-64
122. Parker LA, Gilles T. 1995. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav. Neurosci. 109:71-78
123. Onaivi ES, Green MR, Martin BR. 1990. Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther. 253:1002-9
124. Harris RT, Waters W, McLendon D. 1974. Evaluation of reinforcing capability of delta-9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacologia 37:23-29
125. Leite JR, Carlini EA. 1974. Failure to obtain cannabis-directed behaviour and abstinence syndrome in rats chronically treated with Cannabis saliva extracts. Psychopharmacologia 36:133-45
126. Corcoran ME, Amit Z. 1974. Reluctance of rats to drink hashish suspensions: free-choice and forced consumption, and the effects of hypothalamic stimulation. Psychopharmacologia 35:129-47
127. McGregor IS, Bryant PA, Arnold J. 1995. CP55,940, a synthetic cannabinoid, does not sensitize locomotor activity or cocaine responsitivity with intermittent administration in Wistar rats. Soc. Neurosci. Abstr. 21:726
128. Takahashi RN, Singer G. 1981. Cross self-administration of delta 9-tetrahydrocannabinol and D-amphetamine in rats. Braz. J. Med. Biol. Res. 14:395-400
129. Sanudo-Pena MC, Tsou K, Delay ER, Hohmann AG, Force M, et al. 1997. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci. Lett. 223:125-28
130. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, et al. 1997. Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. NeuroReport 8:491-96
131. Aberman J, Carriero D, Hill A, Makriyannis A, Salamone J. 1997. Behavioural effects of cannabinoid agonists and antagonists. Symposium on Cannabinoids, 1:42. Burlington, VT: Int. Cannabinoid Res. Soc.
132. Glass M, Faull RLM, Dragunow M. 1993. Loss of cannabinoid receptor in the substantia nigra in Huntington's disease. Neuroscience 56:523-27
133. Richfield EK, Herkenham M. 1994. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36:577-84
134. Welch SP, Thomas C, Patrick GS. 1995. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:310-21